Rybelsus in Adults 65 and Older: A Clinical Guide to Geriatric Use and Transition to Adult Care

Does the Rybelsus dose change after 65?

No. The label gives one adult titration and no separate schedule for older patients [1]. Days 1 to 30 are 3 mg once daily, a dose the label states is not effective for glycemic control. Days 31 to 60 are 7 mg once daily. From day 61 the choice is to stay at 7 mg when no further glycemic control is needed or to increase to 14 mg [1]. Only one tablet is taken per day [1].

Rybelsus and Ozempic tablets are not substitutable milligram for milligram; the label pairs Rybelsus 7 mg and 14 mg with Ozempic tablets 4 mg and 9 mg as equivalent maintenance steps [1].

How much of the evidence comes from people in their 70s and 80s?

Less than the phrase 'adults 65 and older' suggests. In the two placebo-controlled trials behind the label's safety tables, 1,071 patients took semaglutide tablets, the mean age was 58 and 3.9% were 75 or older; across nine placebo- and active-controlled trials, 4,116 patients took the tablets, the mean age was 58 and 5% were 75 or older [1]. PIONEER 1, the monotherapy trial, enrolled 703 patients with a mean age of 55 [2].

The 30-minute rule and other morning medicines

The label says to take one tablet on an empty stomach in the morning with up to 4 ounces of water and no other liquid, swallowed whole and not split, crushed, chewed or dissolved, then to wait at least 30 minutes before food, any other drink or any other oral medicine. A missed dose is skipped and the next one taken the following day [1].

Semaglutide delays gastric emptying and can change the absorption of other oral drugs, and the label advises closer clinical or laboratory monitoring for oral drugs with a narrow therapeutic index or that require clinical monitoring [1]. In a drug interaction study, levothyroxine exposure (AUC) increased 33% when it was given with semaglutide tablets [1].

GI reactions, dehydration and kidney function

In the pooled placebo-controlled trials, nausea occurred in 6% on placebo, 11% on 7 mg and 20% on 14 mg; diarrhea in 4%, 9% and 10%; vomiting in 3%, 6% and 8%; constipation in 2%, 6% and 5%; and abdominal pain in 4%, 10% and 11% [1]. Any gastrointestinal reaction occurred in 21%, 32% and 41% respectively, severe GI reactions in 0.3%, 0.6% and 2%, and treatment was stopped for GI reasons in 1%, 4% and 8% [1]. The label notes that most nausea, vomiting and diarrhea occurred during dose escalation [1].

The label also warns about acute kidney injury from volume depletion, with most reported cases following gastrointestinal reactions that cause dehydration such as nausea, vomiting or diarrhea, and advises monitoring renal function in patients reporting those reactions, especially during initiation and escalation [1]. Rybelsus is not recommended in patients with severe gastroparesis [1].

Hypoglycemia when insulin or a sulfonylurea is on board

The label warns that combining Rybelsus with an insulin secretagogue such as a sulfonylurea, or with insulin, raises the risk of hypoglycemia including severe hypoglycemia, and that reducing the dose of the sulfonylurea or insulin may lower that risk when Rybelsus is started [1]. In a 52-week study of Rybelsus added to insulin, glucose below 54 mg/dL occurred in 32% of the placebo group, 26% of the 7 mg group and 30% of the 14 mg group [1].

Cardiovascular risk reduction

The label indicates Rybelsus to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — in adults with type 2 diabetes who are at high risk for these events [1]. SOUL randomized 9,650 adults aged 50 or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both to oral semaglutide up to 14 mg daily or placebo; over a median follow-up of 49.5 months, a primary event occurred in 12.0% versus 13.8% (HR 0.86, 95% CI 0.77 to 0.96) [3]. PIONEER 6, in 3,183 adults at high cardiovascular risk with a mean age of 66, found events in 3.8% versus 4.8% (HR 0.79, 95% CI 0.57 to 1.11) over a median 15.9 months; that trial was built to rule out excess cardiovascular risk, not to prove benefit [4].

Other label warnings that apply at any age

The boxed warning covers thyroid C-cell tumors in rodents at clinically relevant exposures, with human relevance unknown, and Rybelsus is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1]. The label also covers acute pancreatitis (discontinue if suspected), acute gallbladder disease, serious hypersensitivity reactions including anaphylaxis and angioedema, and diabetic retinopathy complications, which were reported in 4.2% of patients on semaglutide tablets versus 3.8% on comparator in pooled glycemic trials, with monitoring advised for patients who have a history of retinopathy [1]. Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists, and patients are instructed to tell healthcare providers about planned surgeries or procedures [1]. The prescribing information says to discontinue Rybelsus or Ozempic tablets at least 2 months before a planned pregnancy and does not recommend breastfeeding during treatment because SNAC and/or its metabolites are present in human milk and could pose a risk to the breastfed infant [1].

On vision specifically: the EMA's safety committee concluded in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people and corresponding to about one extra case per 10,000 person-years, and advised stopping treatment if NAION is confirmed [5].

Moving care from a geriatric or specialist clinic to a general adult practice

The label provides one adult dosing schedule, with no separate schedule for patients 65 and older [1]. Because escalation is counted in days from the first tablet, the start date and the current dose are the key details to hand over. Also relevant are current HbA1c, kidney function, the other glucose-lowering drugs in use (especially insulin and sulfonylureas), any other oral medicines taken in the morning, and planned surgery or sedation given the aspiration warning [1]. Taking the tablet with breakfast is outside the label's instructions [1].